Phase 2 randomized clinical study of a Rho kinase inhibitor, k-115, in primary open-angle glaucoma and ocular hypertension

American Journal of Ophthalmology

Volumn 156, Issue 4, 2013, Pages

  Tanihara, Hidenobu ^a   Inoue, Toshihiro ^a   Yamamoto, Tetsuya ^b   Kuwayama, Yasuaki ^c   Abe, Haruki ^d   Araie, Makoto ^e  

^a KUMAMOTO UNIVERSITY   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c Fukushima Eye Clinic   (Japan)

^d NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^e The Mutualaid Association of Public School Teachers)   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

K 115; PLACEBO; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; OPTIMAL DRUG DOSE; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84884595041     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2013.05.016     Document Type: Article

References (11)

1. A. Sommer, J.M. Tielsch, and J. Katz Racial differences in the cause-specific prevalence of blindness in east Baltimore N Engl J Med 325 20 1991 1412 1417
2. H.A. Quigley Glaucoma. Lancet 377 9774 2011 1367 1377
3. A. Bagnis, M. Papadia, R. Scotto, and C.E. Traverso Current and emerging medical therapies in the treatment of glaucoma Expert Opin Emerg Drugs 16 2 2011 293 307
4. M. Honjo, H. Tanihara, and M. Inatani Effects of Rho-associated protein kinase inhibitor, Y-27632, on intraocular pressure and outflow facility Invest Ophthalmol Vis Sci 42 1 2001 137 144 (Pubitemid 32059420)
5. T. Koga, T. Koga, M. Awai, J. Tsutsui, B.Y. Yue, and H. Tanihara Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells Exp Eye Res 82 3 2006 362 370 (Pubitemid 43138949)
6. T. Kameda, T. Inoue, and M. Inatani The effect of Rho-associated protein kinase inhibitor on monkey Schlemm's canal endothelial cells Invest Ophthalmol Vis Sci 53 6 2012 3092 3103
7. H. Tokushige, M. Inatani, and S. Nemoto Effects of topical administration of Y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys Invest Ophthalmol Vis Sci 48 7 2007 3216 3222 (Pubitemid 351261166)
8. P.V. Rao, P.F. Deng, J. Kumar, and D.L. Epstein Modulation of aqueous humor outflow facility by the rho kinase-specific inhibitor Y-27632 Invest Ophthalmol Vis Sci 42 5 2001 1029 1037 (Pubitemid 32289800)
9. H. Tanihara, M. Inatani, M. Honjo, H. Tokushige, J. Azuma, and M. Araie Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers Arch Ophthalmol 126 3 2008 309 315 (Pubitemid 351398453)
10. R.D. Williams, G.D. Novack, T. van Haarlem, C. Kopczynski AR-12286 Phase 2A Study Group Ocular hypotensive effect of the rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension Am J Ophthalmol 152 5 2011 834 841
11. Tanihara H, Inoue T, Yamamoto T, et al. Phase 1 clinical trials of a selective rho kinase inhibitor, K-115. JAMA Ophthalmol. Forthcoming.